Shamburg News · 8-K filed Nov 13, 2026, 4:05 PM EST

Enveric Biosciences Reports Third Quarter 2026 Financial Results and Corporate Update

ENVB · Enveric Biosciences, Inc.

  • Earnings
  • Other event
  • Materiality: high

Enveric Biosciences reported a net loss attributable to stockholders of $2.5 million, or $0.57 per basic and diluted share, for the third quarter ended September 30, 2026, compared with a net loss of $3.4 million, or $10.81 per share, a year earlier. The company had cash-on-hand of $5.6 million as of September 30, 2026. The release also provided an update on preclinical EB-003 development, including qEEG, ADMET and GloSensor results, and a U.S. patent allowance for mescaline derivatives in the EVM401 Series.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001493152-26-051708.

Written from the filing by Shamburg Markets. Figures are as reported by the company.